Grifols, S.A. (GRFS) Shares Bought by Advisor Group Inc.
Advisor Group Inc. grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,471 shares of the biotechnology company’s stock after purchasing an additional 309 shares during the quarter. Advisor Group Inc.’s holdings in Grifols, were worth $242,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Grifols, in the second quarter valued at about $57,845,000. FMR LLC lifted its stake in shares of Grifols, by 52.6% in the first quarter. FMR LLC now owns 6,352,581 shares of the biotechnology company’s stock valued at $119,905,000 after buying an additional 2,189,431 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Grifols, by 14,219.5% in the second quarter. Ameriprise Financial Inc. now owns 1,901,199 shares of the biotechnology company’s stock valued at $40,153,000 after buying an additional 1,887,922 shares during the period. AKO Capital LLP lifted its stake in shares of Grifols, by 5.7% in the second quarter. AKO Capital LLP now owns 12,341,363 shares of the biotechnology company’s stock valued at $9,335,000 after buying an additional 667,174 shares during the period. Finally, NGAM Advisors L.P. lifted its stake in shares of Grifols, by 661.8% in the second quarter. NGAM Advisors L.P. now owns 632,072 shares of the biotechnology company’s stock valued at $13,356,000 after buying an additional 549,097 shares during the period. 21.93% of the stock is currently owned by institutional investors.
Several research firms recently weighed in on GRFS. Goldman Sachs Group, Inc. (The) cut shares of Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. BidaskClub cut shares of Grifols, from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Finally, Zacks Investment Research upgraded shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Grifols, has a consensus rating of “Hold” and a consensus target price of $24.00.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/17/grifols-s-a-grfs-shares-bought-by-advisor-group-inc.html.
Shares of Grifols, S.A. (GRFS) opened at 21.50 on Tuesday. Grifols, S.A. has a 1-year low of $14.27 and a 1-year high of $22.83. The company has a 50 day moving average of $21.08 and a 200 day moving average of $20.85. The company has a market cap of $29.38 billion, a PE ratio of 43.74 and a beta of 0.98.
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).
Receive News & Stock Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related stocks with our FREE daily email newsletter.